NGNE - How Peter Marks' FDA departure is impacting pharma, biotech stocks
2025-03-31 12:37:32 ET
More on Beam, CRISPR Therapeutics
- Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
- CRISPR Therapeutics Set To Reach Previous Heights
- Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
- Beam upgraded to Buy at BofA Securities on recent genetic condition treatment
- Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S.